Top 5 Pharma Company Signs 5-Year Multi-Million Dollar Agreement for OmniComm System's TrialOne Application Suite
FORT LAUDERDALE, Fla., June 3, 2013 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTC:OMCM.OB), one of the fastest growing companies in the EDC marketplace, today announced that its TrialOne(R) suite of applications has been chosen by a top 5 pharmaceutical company to automate their global clinical trial operations and processes in all their early-phase clinics.
TrialOne is a web-based, mobile, clinic automation solution designed specifically for early-phase research to facilitate recruitment, appointment scheduling, study building and design, screening, source data capture, sample tracking and reporting. TrialOne offers time-based data entry and integration with bar-code scanners and printers and biomedical monitoring devices to automate data, sample collection and processing. The flexible and configurable workflow streamlines operational and data management processes, while enhancing protocol compliance and data quality.
The clinics will be implementing the entire TrialOne suite, including Sample Tracking, Direct Data Capture, and Subject Recruitment & Screening and the implementation will be centralized and hosted by OmniComm and accessed via the web to accommodate a standardized workflow across all clinics.
RealPennies.com: RealPennies.com: (OTCBB:OMCM) OmniComm Systems, Inc.
Aug 21, 2008 (M2 PRESSWIRE via COMTEX) -- Are you a public company looking for exposure? Contact RealPennies.com - 1-646-417-8211
For more info: http://omcm.realpennies.com/
Systems Medicine LLC Uses OmniComm Systems, Inc. for Electronic Data Capture in a Phase II Oncology Study Wednesday August 20, 3:55 pm ET
Phase II Multicenter Studies to Benefit From the First in Functionality Features of TrialMaster for EDC
FT. LAUDERDALE, FL -- OmniComm Systems, Inc. , a leader in integrated EDC solutions for clinical trials, recently announced that the company is providing EDC software and services for a Phase II trial in BRCA 1/2 and HNPCC patients sponsored by the Tucson Arizona based biotech, Systems Medicine LLC . SML initially began its relationship with OmniComm through OmniComm's CRO Preferred Program and then selected OmniComm as its EDC vendor of choice for their Phase II study.
"Our initial experience in working with OmniComm was very favorable and as a result we chose to use them in our next trial. We were impressed with their responsiveness and professionalism throughout the entire negotiation and study build process," said Patrick Shannon, Ph.D., Senior Director Project Management for Systems Medicine LLC.
Systems Medicine, LLC develops oncology products by integrating predictive cellular pharmacogenomics with world-class clinical and regulatory expertise. This allows SML to develop patient-selective therapies by defining the context of vulnerability of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. For more information on SML and the products that SML has in development, please visit www.systems-medicine.com.
"Research organizations are looking at EDC as a strategic imperative to help maximize their investments in recently's highly competitive clinical research environment," said Stephen Johnson, COO of OmniComm. "OmniComm is privileged to be partnering with companies like SML that are delivering cutting edge cancer treatments to the marketplace. It gives us great satisfaction to know that our TrialMaster EDC solution helps to speed up that process."
OmniComm Systems, Inc. provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.
LAST $0.47 USD
Read our full disclaimer at: http://www.realpennies.com
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/content/view/42
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
CONTACT: RealPennies Tel: +1 646 417 8211 e-mail: email@example.com WWW: http://www.realpennies.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to firstname.lastname@example.org.
(C)1994-2008 M2 COMMUNICATIONS LTD